Literature DB >> 33034385

IL-1/IL-1R signaling induced by all-trans-retinal contributes to complement alternative pathway activation in retinal pigment epithelium.

Xinxuan Cheng1,2,3, Danxue He1,2,3, Chunyan Liao1,2,3, Sijie Lin1,2,3, Liying Tang1,2,3, Yuan-Liang Wang4,5, Jiaoyue Hu1,2,3, Wei Li1,2,3, Zuguo Liu1,2,3, Yalin Wu1,2,3, Yi Liao1,2,3.   

Abstract

The underlying mechanisms of complement activation in Stargardt disease type 1 (STGD1) and age-related macular degeneration (AMD) are not fully understood. Overaccumulation of all-trans-retinal (atRAL) has been proposed as the pathogenic factor in both diseases. By incubating retinal pigment epithelium (RPE) cells with atRAL, we showed that C5b-9 membrane attack complexes (MACs) were generated mainly through complement alternative pathway. An increase in complement factor B (CFB) expression as well as downregulation of complement regulatory proteins CD46, CD55, CD59, and CFH were observed in RPE cells after atRAL treatment. Furthermore, interleukin-1β production was provoked in both atRAL-treated RPE cells and microglia/macrophages. Coincubation of RPE cells with interleukin-1 receptor antagonist (IL1Ra) and atRAL ameliorated complement activation and downregulated CFB expression by attenuating both p38 and c-Jun N-terminal kinase (JNK) signaling pathways. Our findings demonstrate that atRAL induces an autocrine/paracrine IL-1/IL-1R signaling to promote complement alternative pathway activation in RPE cells and provide a novel perspective on the pathomechanism of macular degeneration.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  all-trans-retinal; complement alternative pathway; complement factor B; interleukin-1β; retinal pigment epithelium

Year:  2020        PMID: 33034385     DOI: 10.1002/jcp.30103

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  1 in total

1.  Systemic complement activation levels in Stargardt disease.

Authors:  Patty P A Dhooge; Esmee H Runhart; Catherina H Z Li; Corrie M de Kat Angelino; Carel B Hoyng; Renate G van der Molen; Anneke I den Hollander
Journal:  PLoS One       Date:  2021-06-25       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.